["Materials and methods", "Ethics statement", "All protocols involving mice followed the guidelines of the Canadian Council on Animal Care (CCAC) and were approved by the ethics committees of the RI-MUHC (project identifier [ID] 2015\u20137656).", "Culture conditions", "Mycobacteria strains were grown in rolling liquid culture at 37\u00b0C in Middlebrook 7H9 (Difco) supplemented with 10% albumin dextrose catalase (ADC), 0.2% glycerol, and 0.05% Tween 80 (7H9 complete) or on 7H10 agar plates supplemented with 10% oleic acid ADC and 0.5% glycerol at 37\u00b0C. When mentioned, the carbon source was modified from glycerol to acetate or the detergent Tween 80 was removed from the media. Bacillus cereus (clinical isolate), Corynebacterium glutamicum (ATCC 13032), Escherichia coli, and Pseudomonas aeruginosa PAO1 were grown in LB broth. HepG2 cells (ATCC HB-8065) were grown in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) with phenol red (from Gibco) supplemented with 10% fetal bovine serum at 37\u00b0C with 5% CO2.", "Compound libraries", "The GSK library contains 176 small molecules with antimycobacterial activity, specifically against Mycobacterium tuberculosis [56]. Medicines for Malaria Venture created two compound sets: the Pathogen Box and the Pandemic Response Box. The Pathogen Box is composed of 400 molecules active against various disease sets (https://www.mmv.org/mmv-open/pathogen-box/about-pathogen-box). The Pandemic Response Box is composed of 400 diverse drug-like molecules broadly categorized as antibacterials (201 molecules), antivirals (153 molecules), and antifungals (46 molecules) (https://www.mmv.org/mmv-open/pandemic-response-box/about-pandemic-response-box).", "Library screening", "MMV Pathogen Box, MMV Pandemic Response Box, and GSK TB-active libraries were screened against M. abscessus ATCC 19977 strain which constitutively expressed the luxCDABE operon (M. abscessus lux) at 10 \u03bcM in duplicate in 96-well flat-bottom plates in 7H9 complete media. The culture was grown to log phase (OD600 0.4\u20130.8) and diluted to OD600 0.005 (5x106 CFU/mL). 90 \u03bcL of culture was mixed with 10\u03bcL of compound. Plates were sealed with parafilm and incubated at 37\u00b0C for 48 hours. Plates had a column of 0.1% DMSO as negative controls (drug-free conditions) and 64 \u03bcg/mL of AMK as positive controls. Luminescence was measured with an Infinite F200 Tecan plate reader. % Luminescence relative to DMSO control was plotted using GraphPad Prism version 9. Compounds that decreased luminescence \u2264 10% were classified as primary hits. Primary hits were screened against M. abscessus ATCC 19977 at 10 \u03bcM in triplicate using REMA (see \u201cDetermination of MIC\u201d below). Plates were setup as performed for the primary screen. Fluorescence was measured with an Infinite F200 Tecan plate reader. % bacteria viability relative to DMSO control was plotted using GraphPad Prism version 9. Compounds that decreased bacteria viability \u2264 10% were classified as confirmed hits. Confirmed hits were followed up with dose-response curves to determine the minimum inhibitory concentration (MIC).", "Determination of minimum inhibitory concentrations (MIC)", "MIC values were determined using the resazurin microtiter assay (REMA). Cultures were grown to log phase (OD600 of 0.4\u20130.8) and diluted to OD600 of 0.005. Drugs were prepared in two-fold serial dilutions in 96-well plates with 90 \u03bcL of bacteria per well to a final volume of 100 \u03bcL. Plates were incubated at 37\u00b0C until drug-free wells were turbid (2 days for M. abscessus). Ten \u03bcL of resazurin (0.025% wt/vol) was added to each well. Once the drug-free wells turned pink (one doubling time), the fluorescence (ex/em 560nm/590nm) was measured using an Infinite F200 Tecan plate reader. Fluorescence intensities were converted to % viable cells relative to drug-free conditions and fit to the Gompertz equation using GraphPad Prism version 9. MIC values at 90% growth inhibition were determined from the nonlinear regression Gompertz equation.", "In vitro cytotoxicity in HepG2 cells", "Drugs were prepared in two-fold serial dilutions in 96-well plates with 45 \u03bcL of Human HepG2 cells (2,000 cells/well) to a final volume of 50 \u03bcL. Plates were incubated for 3 days at 37\u00b0C with 5% CO2. Five \u03bcL of resazurin (0.025% wt/vol) was added to each well and incubated for 4 hours at 37\u00b0C. Cell viability was determined from the fluorescence intensity as done in the previous REMA assay. 50% toxic dose concentrations (TD50) values were obtained using a nonlinear regression fit equation ([inhibitor] vs response, variable slope) in GraphPad Prism version 9.", "Assessment of EPT efficacy in infected Zebrafish", "Experiments in zebrafish were conducted according to the Comit\u00e9 d\u2019Ethique pour l\u2019Exp\u00e9rimentation Animale de la R\u00e9gion Languedoc Roussillon under reference 2020022815234677V3. Experiments were performed using the golden mutant and macrophage reporter Tg(mpeg1:mCherry) lines as previously described [57]. Embryos were obtained and maintained as described [27]. Embryo age is expressed as hours post fertilisation (hpf). Green fluorescent M. abscessus CIP104536T (R) expressing Wasabi were prepared and microinjected in the caudal vein (2\u20133 nL containing \u2248100 bacteria/nL) in 30 hpf embryos previously dechorionated and anesthetized with tricaine [58]. The bacterial inoculum was checked a posteriori by injection of 2 nL in sterile PBST and plating on 7H10OADC. Infected embryos were transferred into 6-well plates (12 embryos/well) and incubated at 28.5\u00b0C to monitor kinetics of infection and embryo survival. Survival curves were determined by counting dead larvae daily for up to 11 days, with the experiment concluded when uninfected embryos started to die. EPT treatment of infected embryos and uninfected embryos was commenced at 24 hpi (hours post-infection) for 5 days. The drug-containing solution was renewed daily. Bacterial loads in live embryos were determined by anesthetising embryos in tricaine as previously described [59], mounting on 3% (w/v) methylcellulose solution and taking fluorescent images using a Zeiss Axio Zoom.V16 coupled with an Axiocam 503 mono (Zeiss). Fluorescence Pixel Count (FPC) measurements were determined using the \u2018Analyse particles\u2019 function in ImageJ [58]. All experiments were completed at least three times independently.", "Isolation of resistant mutants", "Early log phase M. abscessus (OD600 0.1\u20130.4) was cultured and resuspended to an OD600 of 10. Ten mL of culture was kept as a reference strain for future sequencing. One hundred \u03bcL of OD600 10 (approx. 1 X 109 CFU/100\u03bcL) was plated on solid media containing 10X, 20X, or 40X MIC90 of the compound of interest. AMK was used as a control antibiotic. Plates were incubated for 5 days at 37\u00b0C. Number of colonies were counted to obtain mutation frequencies. Resistant colonies were transferred into fresh media without antibiotics (to avoid the emergence of secondary mutations). The MIC (REMA method) was measured for the mutant against the compound of interest as well as a panel of reference compounds with different targets for negative controls.", "Sequencing resistant mutants", "Genomic DNA (gDNA) was extracted from the 10 mL reference aliquot of M. abscessus harvested during mutant isolation and fresh cultures of mutant strains with confirmed resistance (REMA method) using the Qiagen QIAamp UCP Pathogen Mini kit with a modified mechanical lysis protocol. Pellet culture by centrifugation and resuspend in 590 \u03bcL of ATL buffer containing the Dx reagent in a low-bind tube. Add 40 \u03bcL of proteinase K (20 mg/mL) and 20 \u03bcL of lysozyme (100 mg/mL) and incubate for 30 minutes at 56\u00b0C under agitation. Transfer into a Pathogen Lysis Tube L and vortex twice using a FastPrep-24 instrument at 6.5 m/s for 45 s with a 5-minute incubation on ice in between. Transfer supernatant into fresh 2 mL low-bind tube. Follow manufacturer\u2019s instructions for sample prep with spin protocol. gDNA was quantified with Quant-iT PicoGreen dsDNA kit. leuS from ATCC 19977 and EPT mutants was sequenced with Sanger Sequencing with the primers listed in S5 Table.", "Cloning and over-expressing mutant leuS in M. abscessus", "Wildtype and mutant leuS (D436H) were PCR amplified from gDNA using Phusion with primers 1 & 2 (see S5 Table), ligated into pMV306_hsp60 digested with EcoRV and HindIII restriction enzymes, and transformed into E. coli DH5\u03b1 cells (Promega). Plasmids were extracted and sequenced with primers 3\u201312 (see S5 Table) using Sanger sequencing.", "Protein purification", "The M. abscessus LeuRS editing domain (residues 303\u2013499 of WP005112800.1) and the M. tuberculosis LeuRS editing domain (residues 311\u2013512 of WP_003900794.1) were synthesized with an N-terminal polyhistidine tag and tobacco etch virus (TEV) protease recognition site, with codon optimization for E. coli and cloned into pET24a(+) by the company BioBasic to create pMabsED and pMtbED, respectively. E. coli BL21 (DE3) cells were transformed with pMabsED or pMtbED and grown overnight at 37\u00b0C on LB-agar with 50 \u03bcg/mL kanamycin. Single colonies were transferred into 100 mL of LB media with 50 \u03bcg/mL kanamycin (LB-kan) and grown overnight at 37\u00b0C. One liter of LB-kan was inoculated with 10 mL of the overnight culture and grown at 37\u00b0C until an optical density at 600 nm of 0.6 was reached. Protein expression was then induced with addition of 0.5 mM IPTG and the culture further incubated for 18 h at 16\u00b0C. The cells were harvested by centrifugation (4000 g for 20 min), resuspended in buffer A (50 mM Tris, 150 mM NaCl, 2 mM BME) plus 2 mM PMSF, lysed using sonication (55% amplitude, 30 cycles of 10s on 20s off) and the lysate clarified by ultracentrifugation (40,000 g for 30 min). The lysate was loaded onto a HiTrap FF (Cytiva) and eluted with buffer A plus 500 mM imidazole. The eluate was dialyzed in buffer A, digested with TEV protease overnight and the protease as well as non-cleaved protein separated from cleaved protein by application to the HiTrap FF column with flow-through collected. Protein was then subjected to size exclusion chromatography using a HiLoad Superdex Increase 75 colum (Cytiva), with fractions containing pure protein pooled.", "Isothermal titration calorimetry", "ITC measurements were performed at 30\u00b0C on a VP-ITC system (Malvern Panalytical Inc). Epetraborole (100 \u03bcM) in measurement buffer (50 mM Tris, 150 mM NaCl, 2 mM BME, 10 mM AMP) was titrated with protein solution (1 mM) in measurement buffer over 29 injections of 10 \u03bcl with 300 seconds equilibration time between injections. The heat evolved after each protein injection was calculated by integrating the calorimetric signal. The binding isotherms obtained were fitted to a single-site model using Origin 7 (Microcal Inc.). Experiments were performed in triplicates.", "Crystallography", "Initial crystals of the M. abscessus LeuRS editing domain were obtained from sparse matrix screening in 96-well sitting drop format using a sample of 10 mg/mL protein in buffer A, and a precipitant solution of 100 mM HEPES pH 7.0 and 2 M ammonium sulfate, at room temperature. Diffraction-quality crystals were grown by mixing 2 \u03bcL of protein solution (7.5 mg/mL) and 2 \u03bcL of reservoir solution (100 mM HEPES pH 7.0 and 2.5 M ammonium sulfate) in 24-well sitting-drop format. Crystals were cryoprotected in 100 mM HEPES pH 7.0 and 3.5 M ammonium sulfate, looped and flash-vitrified in liquid nitrogen. Diffracting co-crystals of the editing domain and epetraborole were obtained by streak seeding un-liganded crystals shards into drops in 24-well sitting-drop format with a reservoir solution of 100 mM HEPES, pH 7.5, 2% PEG400, 2.1 M ammonium sulfate, 10 mM AMP, 1 mM epetraborole and 15% glycerol at room temperature. These crystals were directly looped and flash-vitrified in liquid nitrogen for diffraction experiments.", "Structure determination", "Diffraction data for the unliganded editing domain was collected at the Advanced Photon Source (24-ID-E) and data for the epetraborole\u2013editing domain complex at the Canadian Light Source (CMCF-08B1-1). The data sets were indexed, processed, and scaled with HKL2000 [60] (for the unliganded editing domain) or DIALS [61] (for the complex). Initial phases for the M. abscessus LeuRS editing domain were obtained using molecular replacement with the program Phaser [62] using 5AGR [19] as a search model. Iterative rounds of refinement with Phenix [63] and manual modeling in Coot [64] yielded the final unliganded structure. The structure of the M. abscessus LeuRS editing domain with epetraborole bound in the active site crystallized in a different crystal form (S5 Table). Therefore, initial phases for the co-complex structure were obtained with molecular replacement using the program Phaser [62] utilizing the unliganded structure as a search model. The model for epetraborole was generated with eLBOW [65] and geometrical restraints were obtained with AceDRG [66]. Iterative rounds of refinement using Phenix [63] and manual modeling in Coot [64] yielded the final co-complex structure.", "Time-kill assays", "Log phase (OD600 of 0.4\u20130.8) M. abscessus was diluted to an OD600 of 0.0001 (105 CFU/mL) and incubated with drugs of interest. One hundred \u03bcL aliquots were taken and serially diluted in 7H9 complete and plated on 7H10 agar. The starting inoculum was determined from time 0 before drugs were added. CFUs were determined after 4 days of incubation at 37\u00b0C. Bactericidal activity is defined as a 3 log10 decrease (99.9%) from the starting inoculum.", "Checkerboard assays", "Drug combinations were assessed for synergy, indifference, or antagonism using the standard checkerboard format followed by REMA for MIC determination. Fractional inhibitory concentrations (FICs): FIC (X+Y) = (MIC of X in combination with Y)/(MIC of X alone). The fractional inhibitory concentration index (FICI) was calculated from FICX + FICY. FICI values < 0.5 are defined as synergy, FICI values \u2265 4.0 are defined as antagonism, and FICI values in between are defined as indifferent. EPT was serially diluted two-fold from 4X MIC to 1/16 X MIC. Mycobacterial drugs were serially diluted two-fold from 8X MIC to 1/32X MIC.", "Inducible resistance assay", "To test whether M. abscessus has inducible resistance to EPT, we performed a preexposure assay. Briefly, log phase M. abscessus was diluted to 0.05 and grown overnight with \u00bc X MIC50 of EPT (0.016 \u03bcg/mL) and CLR (0.016 \u03bcg/mL). After overnight growth, MICs were determined via REMA. Data is reported as the ratio of pre-exposed culture MIC to MIC of culture grown in drug-free conditions.", "CRISPRi conditional knockdown of leuS", "The PLJR962 plasmid was restriction digested with BsmBI and gel purified. Synthetic oligo primers (S4 Table) for the sgRNA with the PAM sequence for leuS were annealed and ligated into digested PLJR962 vector and transformed into E. coli DH5\u03b1. Clones were sequenced using sequencing primer (S4 Table). 500 ng of CRISPRi leuS vector was electroporated into M. abscessus ATCC 19977. Colonies were picked from 7H10 plates containing 250 \u03bcg/mL kanamycin and confirmed by PCR. M. abscessus CRISPRi leuS was grown in liquid culture to early log phase (OD600 0.1\u20130.4) and diluted to 1x104 CFU/mL. One hundred \u03bcL of culture was plated on 7H10 containing either serial dilutions of EPT or RFB as control, and 0, 0.05 \u03bcg/mL, or 0.1 \u03bcg/mL ATc, the inducer of the sgRNA and catalytically inactive Cas9 (dCas9). The MIC99 is the concentration of EPT or RFB that prevented growth relative to the drug free plate.", "Norvaline suppression of mutants", "Early log phase M. abscessus or M. tuberculosis (OD600 0.1\u20130.4) was cultured and resuspended to an OD600 of 10 (M. abscessus) or OD600 of 1 (M. tuberculosis). One hundred \u03bcL of culture (approx. 1 X 109 CFU for M. abscessus and 1 x 106 CFU for M. tuberculosis) was plated on solid media containing 10X MIC90 EPT, 10X MIC90 EPT + 590 \u03bcg/mL norvaline, or 590 \u03bcg/mL norvaline. The experiment was repeated with 10X MIC90 RFB as control. M. abscessus plates were incubated for 5 days at 37\u00b0C, M. tuberculosis plates were incubated for 5 weeks at 37\u00b0C. Number of colonies were enumerated to obtain mutation frequencies. Since, mutations are considered rare events, mutation frequency rates between 10X MIC90 EPT and 10X MIC90 EPT + 590 \u03bcg/mL norvaline were compared using the two Poisson rates.", "The Poisson rate is defined as the number of events divided by the sample size: \u03bb = X/N", "The rates were compared using the small sample z-test:\n\nzSR=\u03bb2\u2212\u03bb1121N1+1N2", "LC-MS/MS measurement of norvaline in the proteome", "Wildtype, mutant, and complement M. abscessus strains were grown for 12 h or 3 days in 59 \u03bcg/mL norvaline or 59 \u03bcg/mL valine. Proteins were extracted using an optimized protocol for mass spectrometry follow-up [67]. Cells were collected, washed with ice-cold PBS, and resuspended in 1mL lysis buffer (50 mM NH4HCO3 pH 7.4, 10 mM MgCl2, 0.1% NaN3, 1 mM EGTA, 1 x protease inhibitors (Roche), 7 M urea, and 2 M thiourea). Cells were lysed with zirconia beads and the cell lysate was collected and filtered through a 0.22 \u03bcm membrane. Proteins were precipitated overnight at 4\u00b0C with TCA at 25% (v/v). The precipitate was washed with 1 mL cold acetone and 250 \u03bcL cold water. The final wash is only water. The pellet was resuspended in 200 \u03bcL resuspension buffer (50 mM NH4HCO3, 1 M urea). Protein extraction was quantified with the Bradford assay and the quality of proteins was examined on SDS-PAGE. Protein lysates were dissolved in SDS-PAGE reducing buffer and electrophoresed onto a single stacking gel band to remove lipids, detergents and salts. For each sample, a single gel band was reduced with DTT (Sigma), alkylated with iodoacetic acid (Sigma) and digested with LCMS grade trypsin (Promega). Extracted peptides were re-solubilized in 0.1% aqueous formic acid and loaded onto a Thermo Acclaim Pepmap (Thermo, 75 \u03bcM ID X 2 cm C18 3 \u03bcM beads) precolumn and then onto an Acclaim Pepmap Easyspray (Thermo, 75 \u03bcM X 15 cm with 2 \u03bcM C18 beads) analytical column separation using a Dionex Ultimate 3000 uHPLC at 250 nl/min with a gradient of 2\u201335% organic (0.1% formic acid in acetonitrile) over 2 hours. Peptides were analyzed using a Thermo Orbitrap Fusion mass spectrometer operating at 120,000 resolution for MS1 with HCD sequencing at top speed (15,000 resolution) for all peptides with a charge of 2+ or greater. The raw data were converted into *.mgf format (Mascot generic format) for searching using the Mascot 2.5.1 search engine (Matrix Science) against Mycobacterium abscessus protein sequences (Uniprot downloaded 2020.11.30). A modification for Xle->Val was used to detect incorporation of Val into WT sequences. The database search results were loaded onto Scaffold Q+ Scaffold_4.4.8 (Proteome Sciences) for statistical treatment and data visualization.", "Murine model of chronic M. abscessus infection using NOD.CB17-Prkdcscid/NCrCrl mice", "RFB (Sigma), EPT (Cayman Chemical), and norvaline (Sigma) were dissolved in 0.5% w/v sterile low viscosity carboxymethyl cellulose pH 7 (vehicle). Drugs were aliquoted and stored at -20\u00b0C for the duration of the 10-day treatment. 6\u20138 weeks-old female mice were ordered from Charles River Labs. Mice were intranasally infected with ~106 CFU (25 \u03bcL of 5x108 CFU/mL) of M. abscessus CIP 104536T (rough morphotype). Five mice were sacrificed 4 hours post-infection to determine initial lung inoculum and on day 1 to enumerate CFU prior to drug administration. Mice were treated daily by oral gavage with 100 \u03bcL of vehicle or drug. On day 11, mice were humanely euthanized, the lungs were collected and homogenized in 1mL of 7H9 complete. Lung homogenates were plated on 7H11 agar and plates were incubated at 37\u00b0C for 5 days. CFU data was log-transformed for one-way ANOVA with Tukey\u2019s multiple comparisons test using GraphPad Prism version 9."]